Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements.
NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare.
The company plans to raise $30 million by offering 4.3 million shares at a price range of $6 to $8.
Amgen reported its fourth-quarter financials yesterday, but in anticipation of this year’s hot merger-and-acquisition market, a lot of focus has been on the company’s considerable available cash.
Only a week after launch, Partner Therapeutics acquired the global rights to Leukine from Sanofi.
The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash.
Seattle Genetics is paying $10 per share in cash for Cascadian.
With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be.
A look at three small biotechs that big drugmakers are drooling over.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.